title: Radiolabelled somatostatin analogue treatment in gastroenteropancreatic neuroendocrine tumours: factors associated with response and suggestions for therapeutic sequence: response to comments by Ezziddin et al.
authors.affiliation: Department of Medical and Surgical Sciences, S. Orsola-Malpighi Hospital, University of Bologna, Bologna, Italy, davide.campana@unibo.it.
authors.forename: Davide
authors.initials: D
authors.lastname: Campana
authors.forename: Gianfranco
authors.initials: G
authors.lastname: Delle Fave
authors.forename: Massimo
authors.initials: M
authors.lastname: Falconi
authors.forename: Paola
authors.initials: P
authors.lastname: Tommassetti
mesh_terms: D005260:Female; D006801:Humans; D007414:Intestinal Neoplasms / Q000532:radiotherapy*; D008297:Male; D018358:Neuroendocrine Tumors / Q000532:radiotherapy*; D015282:Octreotide / Q000031:analogs & derivatives*; D009942:Organometallic Compounds / Q000627:therapeutic use*; D010190:Pancreatic Neoplasms / Q000532:radiotherapy*; D019275:Radiopharmaceuticals / Q000627:therapeutic use*; D013004:Somatostatin / Q000031:analogs & derivatives*; D013274:Stomach Neoplasms / Q000532:radiotherapy*
chemical_list: D009942:Organometallic Compounds; D019275:Radiopharmaceuticals; D013004:Somatostatin; D015282:Octreotide